Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

I. Introduction Drugs that can cure most tuberculosis (TB) patients have been available since the 1950s, yet TB remains the world’s most important cause of death from an infectious agent, besides the human immunodefficiency virus (HIV) with which it is intimately linked (1). TB control is high on the international public health agenda, not just because of the enormous burden of the disease, but also because short-course chemotherapy is recognized to be among the most cost-effective of all health interventions (2, 3). The evidence from studies of the burden on health and cost-effectiveness have been central to promotion of the World Health Organization’s DOTS strategy, and the enhanced Stop TB Strategy, which combine best practices in the diagnosis and treatment of patients with active TB (4-6).

Original publication

DOI

10.3109/9781420090239-4

Type

Chapter

Book title

Tuberculosis: Fourth Edition: The Essentials

Publication Date

01/01/2016

Pages

1 - 22